Target expression details
Target General Information | |||||
---|---|---|---|---|---|
Target ID | T67079 | ||||
Target Name | Interleukin-9 | ||||
Synonyms | IL-9; P40 cytokine; T-cell growth factor P40; IL9 | ||||
Target Type | Clinical Trial | ||||
Gene Name | IL9 | ||||
Biochemical Class | Cytokine: interleukin | ||||
UniProt ID | IL9_HUMAN | ||||
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
Disease | Asthma | ||||
Example drug | MEDI-528 | Phase 2 | [1], [2], [3], [4], [5], [6] | ||
Tissue | Nasal and bronchial airway | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.03 Z-score: -0.09 P-value: 8.78E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
![]() |
|||||
Reference | |||||
REF 1 | ClinicalTrials.gov (NCT00968669) A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults. U.S. National Institutes of Health. | ||||
REF 2 | ClinicalTrials.gov (NCT00394654) A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma | ||||
REF 3 | ClinicalTrials.gov (NCT00483041) A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528 | ||||
REF 4 | ClinicalTrials.gov (NCT00507130) A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma | ||||
REF 5 | ClinicalTrials.gov (NCT00590720) A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma | ||||
REF 6 | NCBI GEO: archive for functional genomics data sets--update. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.